What is the appropriate evaluation and management for a newly diagnosed renal mass in an adult patient with no significant past medical history?

Evaluation of a Newly Found Renal Mass

Obtain high-quality multiphase cross-sectional abdominal imaging (CT or MRI with IV contrast) to characterize the mass, followed by comprehensive metabolic panel, complete blood count, urinalysis, and chest imaging to evaluate for metastases. 1

Initial Imaging Evaluation

Multiphase cross-sectional imaging is mandatory to optimally characterize and clinically stage any solid or complex cystic renal mass. 1 This should include:

• Dedicated renal protocol CT or MRI with assessment of tumor complexity, degree of contrast enhancement, and presence or absence of fat 1
• Unenhanced phase to measure baseline attenuation and identify calcifications 2
• Arterial and nephrographic phases to assess enhancement patterns 2

Key Imaging Thresholds for Decision-Making:

• Homogeneous masses <20 HU or >70 HU on unenhanced CT are benign and require no further workup 2
• Masses 20-70 HU on unenhanced CT are indeterminate and require multiphase evaluation 2
• Homogeneous masses 10-20 HU on portal venous phase contrast CT are benign cysts 2
• Recent evidence suggests masses 21-30 HU on portal venous phase may also be benign cysts and do not require further evaluation 2

MRI is preferred when evaluating local advancement, venous involvement by tumor thrombus, or when iodinated contrast is contraindicated. 3

Laboratory Evaluation

Obtain the following labs in all patients with suspected renal malignancy: [1, 3

• Comprehensive metabolic panel (including serum creatinine for eGFR calculation)
• Complete blood count
• Urinalysis
• Lactate dehydrogenase (LDH)
• C-reactive protein
• Corrected serum calcium
• Alkaline phosphatase
• Liver function tests

Classify chronic kidney disease stage based on eGFR and degree of proteinuria using KDIGO guidelines, as this directly impacts treatment options. 1

Metastatic Evaluation

Chest imaging is mandatory as the lungs are the most common site of metastasis for renal cell carcinoma. [1, 3

Do NOT routinely obtain:

• Bone scan (only if bone pain, elevated alkaline phosphatase, or radiographic findings suggest bony involvement) 4
• Brain imaging (only with acute neurological signs or symptoms) 5
• PET scan (not routinely indicated) 5

Role of Renal Mass Biopsy

Consider renal mass biopsy in specific scenarios: [4, 3

• Before ablative therapies to confirm malignancy 3
• In patients with metastatic disease before starting systemic treatment 3
• When risk/benefit analysis for treatment is equivocal and the patient prefers active surveillance, to provide oncologic risk stratification 4
• For masses that remain indeterminate after optimal cross-sectional imaging 6

Renal mass biopsy provides histopathological confirmation with high sensitivity and specificity. 3

Special Considerations

Genetic counseling should be offered to: 3

• All patients ≤46 years of age
• Patients with multifocal or bilateral renal masses
• Patients with personal or family history suggesting familial renal neoplastic syndrome (von Hippel-Lindau, hereditary leiomyomatosis, etc.)

Approximately 6-9% of renal cancers have germline mutations in cancer predisposition genes. 3

Counseling and Next Steps

A urologist should lead the counseling process and discuss all management options including partial nephrectomy, radical nephrectomy, thermal ablation, and active surveillance. 1 A multidisciplinary team should be involved when necessary. 1

Key counseling points include: 1

• Current perspectives on tumor biology
• Natural history based on size and imaging characteristics
• Oncologic risks versus treatment-related morbidity
• Impact on renal function
• Patient's overall health status, comorbidities, and life expectancy

Common Pitfalls to Avoid

Suboptimal imaging technique is a frequent cause of diagnostic errors—ensure dedicated multiphase renal protocol is used rather than single-phase imaging. 6

Do not assume all enhancing masses are malignant—approximately 20% of surgically resected small renal masses are benign. 7

Avoid radical nephrectomy as first-line treatment for clinical T1a lesions; partial nephrectomy is preferred to preserve renal function. [7, 7

Do not delay nephrology referral in patients with CKD, as appropriate management can prevent further deterioration affecting bone health, metabolic health, and cardiovascular risk. 4